While melanoma rates have been rising over the last 30 years, advancements in treatment and early detection are providing new hope for patients everywhere. In this edition of Guided By Science, we explore melanoma prevention, early detection, and new treatments that are changing the way we treat this deadly disease.
Recently, we filmed a clinical progress video discussing details of our ImmunoPulse therapy and results with Tu Diep: OncoSec’s executive director of clinical development. With over a decade of experience in clinical research, prior to joining OncoSec – including Protox Therapeutics Inc. (now Sophiris Bio Inc.) – Mr. Diep’s experience has been a large asset to our company.
While skin cancer is often caused by UV radiation (around 90% of non-melanoma skin cancers being caused by it), you’re never too old or too tanned to start avoiding skin cancer. Genetic damage in the skin caused by sun exposure permanently increases your chances of skin cancer so the sooner you start avoiding skin cancer the better. Here are a few things you can start acting on, in order to immediately start reducing your risk of getting skin cancer:
This week, our CEO, Punit Dhillon, presented at the 15th Annual Rodman & Renshaw Global Investment Conference. The annual event hosted over 150 established and emerging biotech and pharmaceutical companies. During the presentation, Mr. Dhillon reviewed previous data points and provided an update on upcoming milestones. Here is an overview of the presentation:
Each week at OncoSec, we come across a wide range of news material. This week, we continue our “What We’re Reading” series, with our second instalment. There have been quite a number of recent articles regarding cancer, the biotech industry and treatment methods but we would like to highlight three that you might find interesting and informative.
In biotech, there are many different approaches or veins of science used, in the research and creation of potential treatments, drugs, and delivery methods. For centuries, the health industry has relied on invasive surgery and curative procedures that can have dangerous, long-term side effects for patients. However, there are some newer scientific discoveries that have allowed us to move towards more effective treatment options that are also less damaging to our bodies. One of these categories of research is that of immunotherapy: using the body against disease, instead of relying on as many non-targeted, exterior factors.
Many cancer research and treatment companies create and utilize various methods of treatment. These may be a combination of existing techniques or a new technology developed by the company itself. At OncoSec, one of our treatment methods is ImmunoPulse: a system we’re testing for the treatment of late-stage skin cancer, including merkel cell carcinoma, cutaneous T-cell lymphoma, and metastatic melanoma. With pending announcements surrounding interim data from our phase II trial for metastatic melanoma coming up soon, we would like to review a bit of the description of our ImmunoPulse treatment option currently being tested.